Sensible Biotechnologies Raises $47M to Expand Next-Generation Platform for mRNA Medicines

Sensible Biotechnologies has secured $47 million in financing to expand its innovative mRNA platform technology. The Series A round includes $20 million in non-dilutive funding from the Slovak government and the European Union. The funds will be used to develop a unique platform called VECTOR, which combines AI and high-throughput screening to optimize mRNA sequences for therapeutic use.

The company's PromPT technology helps protect mRNA inside cells during purification for treatment. By harnessing natural cellular machinery, Sensible Biotechnologies aims to produce mRNA with lower immunogenicity and higher protein expression while avoiding double-stranded RNA contamination. This approach reduces reliance on expensive raw materials and manufacturing inputs, enabling more scalable production and expanding mRNA applications to therapies requiring high or repeated dosing.

The new investors joining Sensible Biotechnologies include OTB Ventures, In-Q-Tel, Recode Ventures, Isomer Capital, Y Combinator, Backed VC, Kaya VC, Civilization Ventures, BlueYard Capital, and the family office of Christoph Huber and Tim Garnett.